Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

The present disclosure relates to urinary polyamines useful as prostate cancer biomarkers and a sensitive and specific, method for detecting and quantifying urinary polymaines using lanthanide complexes.

The present invention relates to the diagnosis of prostate disease and the identification of biomarkers in biological samples which can be used in the detection of prostate disease. The invention further relates to the use of the biomarker glycipan-1 (GPC-1) in combination with other biomarkers in diagnostic methods which differentiate between prostate cancer and non-cancerous forms of prostate disease such as benign prostatic hyperplasia.

Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

A method of diagnosing a prostate condition in a subject comprises determining, in a sample obtained from a subject, levels of a plurality of constituents selected from the group consisting of Ca, K, Mg, Zn, Ag, Al, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, Hg, Ho, La, Li, Mn, Na, Nd, Ni, P, Pb, Pr, Rb, S, Sb, Sc, Se, Si, Sm, Sr, Tb, Th, Tl, U, Y, and Zr. A combination of the levels of the plurality of constituents in the sample is compared with a combination of control levels of the same plurality of constituents. A difference between the combinations is indicative of the prostate condition.

Provided is a method of accurate and sensitive characterization and prognosis of prostate cancer in a subject. The method includes obtaining a biological sample from the subject and determining the level of identified biomarkers.

Provided herein are methods for identifying and treating a malignancy in a patient. Aspects of the described methods are performed through use of a computing device. The method comprises receiving at the computing device a plurality of spectra acquired from a corresponding plurality of aliquots containing a biophysiological carrier protein. At least one of a concentration of a spin probe and a concentration of a polar reagent varies between the aliquots. The computing device then determines biophysical parameters based on the received spectra and applies at least parts of the received spectra and the biophysical parameters as an input to a trained logistic regression model. The logistic regression model trained to determine a probability of applied input parameters relating to one or more of a plurality of predetermined diseases and/or disease localisations. The trained model is used to determine a probability of the input parameters relating to one or more of said predetermined diseases and/or disease localisations and outputs a result of the determination, which can be used to determine and then provide proper therapeutic treatments.

Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia. The method comprises initiating androgen deprivation in the individual and administering to the individual an agent capable of inducing apoptosis of vascular endothelial cells within a period of 1-7 days of initiating androgen deprivation.

A method for analyzing a tumor-specific marker and to the use of an isolate from ejaculate for diagnosing and/or monitoring prostate cancer, and/or for monitoring the success of prostate cancer therapy. The method includes the steps of performing an analysis on the isolate, wherein the tumor-specific marker selected from a protein, DNA, and RNA is analyzed, wherein the isolate was obtained by fractionating ejaculate into a low-density cell population and a high-density cell population, wherein the high-density cell population including mature sperm cells was separated and the isolate includes the low-density cell population, wherein the isolate includes a cell pellet.